Argen X SE ADR
Argen X SE ADR (ARGX) Option Chain
Argen X SE ADR trades at $960.04, down 2.17%, with an IV Rank of 69.05%. This is average versus the past year, and the company carries a market cap of $60,377M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $960.00 strike shows calls at $16.20 / $23.50 and puts at $14.80 / $22.80, both carrying about $19.31 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $990.00 calls, at 24 contracts, and the $930.00 puts, at 127, as of Nov 13, 2026.
Read more
Tracking the ARGX option chain helps you see every strike and expiry on Argen X SE ADR in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ARGX options activity at a glance. Use our scanner to monitor the ARGX option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ARGX stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where ARGX options are being actively traded, and where they are not.
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 35.68 | 81 | 0 | 11.11 | 20.04 | 28.00 | 34.30 | 940.00 | -2.09 | 6.00 | 13.40 | 0.00 | 9.70 | 0 | 149 | 64.32 |
| 43.02 | 72 | 0 | 14.36 | 10.04 | 20.50 | 28.30 | 950.00 | -1.05 | 10.00 | 17.30 | 0.00 | 13.65 | 0 | 1 | 56.98 |
| 50.52 | 19 | 0 | 19.81 | 0.04 | 16.20 | 23.50 | 960.00 | -0.00 | 14.80 | 22.80 | 0.00 | 18.80 | 0 | 15 | 49.48 |
| 57.94 | 4 | 0 | 15.65 | 0.00 | 11.90 | 19.40 | 970.00 | +1.04 | 20.70 | 28.00 | 9.96 | 14.39 | 0 | 0 | 42.06 |
| 65.01 | 39 | 2 | 12.10 | 0.00 | 8.30 | 15.90 | 980.00 | +2.08 | 27.20 | 34.00 | 19.96 | 10.64 | 0 | 4 | 34.99 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank69.05% Moderate
- Market cap (M$)60,377
- 52 weeks high-10.51%
- 52 weeks low45.05%
- Analyst recommendationStrong Buy
1.22 - Target price$1,163.83
21.23% above the current stock price - Dividend—
- Payout ratio0.00%
- Earnings date2026-10-22
- P/E36.59
- Future P/E25.65
- EPS (ttm)26.24
- EPS growth next 5 years34.12%
As of Nov 13, 2026